|
Jul 21
|
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis
|
|
Jul 14
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
Jun 30
|
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
|
|
Jun 30
|
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
|
|
Jun 26
|
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
|
|
Jun 24
|
Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera
|
|
Jun 20
|
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity
|
|
May 27
|
Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome
|
|
May 21
|
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
|
|
Apr 16
|
Protagonist Therapeutics Reports Granting of Inducement Award
|
|
Apr 10
|
Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
|
|
Mar 15
|
Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment?
|
|
Mar 13
|
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More
|
|
Mar 12
|
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why
|
|
Mar 11
|
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
|
|
Mar 11
|
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success
|
|
Mar 11
|
J&J and Protagonist’s icotrokinra scores in Phase IIb UC study
|
|
Mar 11
|
Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday
|
|
Mar 10
|
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
|
|
Mar 10
|
Sector Update: Health Care Stocks Decline Late Afternoon
|